Related Experiment Video
Updated: Jul 16, 2025
09:07
Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
Published on: June 11, 2020
5.2K
In vitro oxygen imaging of acellular and cell-loaded beta cell replacement devices
Mrignayani Kotecha1, Longhai Wang2, Safa Hameed3
1Oxygen Measurement Core, O2M Technologies, LLC, Chicago, IL, 60612, USA. mkotecha@oxygenimaging.com.
Scientific Reports
|September 20, 2023
Summary
Electron paramagnetic resonance oxygen imaging (EPROI) assesses oxygen levels in bioartificial pancreas (BAP) devices, crucial for type 1 diabetes treatment. This noninvasive technique ensures cell viability and optimizes BAP design for improved therapeutic outcomes.
Area of Science:
- Biomedical Engineering
- Medical Imaging
- Regenerative Medicine
Background:
- Type 1 diabetes (T1D) involves the loss of insulin-producing beta cells, necessitating cell replacement strategies like bioartificial pancreases (BAPs).
- Hypoxia within BAPs impairs cell function and limits device scalability, posing a significant challenge for achieving long-term insulin independence.
- In vitro oxygen assessment is vital for predicting the in vivo efficacy of BAP devices.
Purpose of the Study:
- To establish protocols for in vitro oxygen imaging of BAP devices using Electron Paramagnetic Resonance Oxygen Imaging (EPROI).
- To evaluate the applicability and accuracy of EPROI for assessing oxygen levels in various BAP configurations.
- To demonstrate EPROI as a quality control tool for developing efficient cell transplantation devices.
Main Methods:
- Utilized a preclinical 720 MHz/25 mT oxygen imager (JIVA-25™) for EPROI measurements.
- Performed pO2 calibration of BAP biomaterials and conducted toxicity studies of the oxygen-sensitive probe trityl OX071.
- Compared EPROI measurements with a single-point probe and performed proof-of-concept in vitro oxygen imaging of five BAP devices.
Main Results:
- EPROI demonstrated compatibility with common BAP biomaterials, and trityl OX071 was found to be non-toxic to various cell types.
- EPROI showed higher accuracy compared to a fluorescent-based point oxygen probe.
- Oxygen mapping of heterogeneous BAP devices highlighted the advantages of EPROI over single-point measurements for assessing oxygen distribution.
Conclusions:
- EPROI is a validated, noninvasive tool for assessing oxygen distribution in BAP devices, crucial for quality control and optimization.
- The developed EPROI protocols are transferable to other cell therapy devices and tissue grafts in regenerative medicine.
- EPROI has the potential to revolutionize the treatment of degenerative diseases like T1D by enabling the development of more effective artificial tissues.
